CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma

Drug Metabolism and Disposition

Volumn 36, Issue 5, 2008, Pages 963-970

  Rahman, Mostafizur ^a,b   Lax, Sigurd F ^c   Sutter, Carrie H ^a   Tran, Quynh T ^a   Stevens, Gaylene L ^a   Emmert, Gary L ^b   Russo, Jose ^d   Santen, Richard J ^e   Sutter, Thomas R ^a,b  

^a UNIVERSITY OF MEMPHIS   (United States)

^b University of Memphis   (United States)

^c General Hospital Graz West   (Austria)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYESTRADIOL; 4 HYDROXYESTRADIOL; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIOL; AROMATASE; AROMATASE ANTIBODY; AROMATASE INHIBITOR; CYTOCHROME P450 1B1; CYTOCHROME P450 1B1 ANTIBODY; ENZYME ANTIBODY; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; UNCLASSIFIED DRUG; VOROZOLE;

ARTICLE; BREAST CARCINOMA; BREAST DUCT; BREAST EPITHELIUM; CANCER INVASION; CATALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BINDING; DRUG DISPOSITION; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROPHOTOMETRY;

ANIMALS; ANTIBODIES; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYTOCHROME P-450 ENZYME SYSTEM; EPITHELIAL CELLS; HUMANS; MALE; MICROSOMES; RABBITS;

EID: 42449135797     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.018960     Document Type: Article

References (41)

1. Aoyama T, Korzekwa K, Nagata K, Gillette J, Gelboin HV, and Gonzalez FJ (1990) Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 126:3101-3106.
2. Brodie A, Lu Q, and Nakamura J (1997) Aromatase in the normal breast and breast cancer. J Steroid Biochem Mol Biol 61:281-286.
3. Bulun SE, Price TM, Aitken J, Mahendroo MS, and Simpson ER (1993) A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77:1622-1628.
4. Buzdar AU (2003) Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res 9:468S-472S.
5. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, et al. (2006) Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 1766:63-78.
6. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Corbin CJ, Graham-Lorence S, McPhaul M, Mason JI, Mendelson CR, and Simpson ER (1988) Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. Proc Natl Acad Sci U S A 85:8948-8952.
8. Cornish-Bowden A (1974) A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 137:143-144.
9. Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55:170-171.
10. Dowsett M, Doody D, Miall S, Howes A, English J, and Coombes RC (1999) Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 56:25-34.
11. Esteban JM, Warsi Z, Haniu M, Hall P, Shively JE, and Chen S (1992) Detection of intratumoral aromatase in breast carcinomas: an immunohistochemical study with clinicopathologic correlation. Am J Pathol 140:337-343.
12. Hamilton A and Piccart M (1999) The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 10:377-384.
13. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, and Sutter TR (1996) 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A 93:9776-9781.
14. Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R, et al. (2000) Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 27:95-112.
15. Joensuu H, Ejlertsen B, Lonning PE, and Rutqvist LE (2005) Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncol 44:23-31.
16. Johnston SR, and Dowsett M (2003) Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3:821-831.
17. Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT, and Sutter TR (2004) Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol 199:210-219.
18. Kudachadkar R and O'Regan RM (2005) Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 55:145-163.
19. Liehr JG and Ricci MJ (1996) 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci U S A 93:3294-3296.
20. Lu Q, Nakmura J, Savinov A, Yue W, Weisz J, Dabbs DJ, Wolz G, and Brodie A (1996) Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137:3061-3068.
21. McFadyen MC, Breeman S, Payne S, Stirk C, Miller ID, Melvin WT, and Murray GI (1999) Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 47:1457-1464.
22. Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, Moriya T, Hirakawa H, Evans DB, Hayashi S, et al. (2007) Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 67:3945-3954.
23. Miller WR (2006) Aromatase and the breast: regulation and clinical aspects. Maturitas 54:335-341.
24. Miller WR (1991) Aromatase activity in the breast tissue. J Steroid Biochem Mol Biol 39:783-790.
25. Montellano PRO (1995) Cytochrome P450 Structure, Mechanism, and Biochemistry, 2nd ed, Plenum Press, New York.
26. Muskhelishvili L, Thompson PA, Kusewitt DF, Wang C, and Kadlubar FF (2001) In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem 49:229-236.
27. Oliveira VM, Piato S, and Silva MA (2006) Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium. Breast Cancer Res Treat 95:235-241.
28. Osborne C and Tripathy D (2005) Aromatase inhibitors: rationale and use in breast cancer. Annu Rev Med 56:103-116.
29. Rahman M, Sutter CH, Emmert GL, and Sutter TR (2006) Regioselective 2-hydroxylation of 17β-estradiol by rat cytochrome P4501B1. Toxicol Appl Pharmacol 216:469-478.
30. Rochat B, Morsman JM, Murray GI, Figg WD, and Mcleod HL (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296:537-541.
31. Sasano H, Anderson TJ, Silverberg SG, Santen RJ, Conway M, Edwards DP, Krause A, Bhatnagar AS, Evans DB, and Miller WR (2005) The validation of new aromatase monoclonal antibodies for immunohistochemistry-a correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol 95:35-39.
32. Schenkman JB, Remmer H, and Estabrook RW (1967) Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol Pharmacol 3:113-123.
33. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, and Sutter TR (1996) Activation of chemically diverse procarcinogens by human cytochrome P-4501B1. Cancer Res 56:2979-2984.
34. Singh S, Chakravarti D, Edney JA, Hollins RR, Johnson PJ, West WW, Higginbotham SM, Cavalieri EL, and Rogan EG (2005) Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma. Oncol Rep 14:1091-1096.
35. Sridar C, Kent UM, Notley LM, Gillam EMJ, and Hollenberg PF (2002) Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther 301:945-952.
36. Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, Li X, Yin H, Cody CW, and Greenlee WF (1994) Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 69:13092-13099.
37. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, and Yokoi T (2006) MicroRNA regulates the expression of human cytochrome P4501B1. Cancer Res 66:9090-9098.
38. Walker NJ, Crofts FG, Li Y, Lax SF, Hayes CL, Strickland PT, Lucier GW, and Sutter TR (1998) Induction and localization of cytochrome P450 1B1 (CYP1B1) protein in the livers of TCDD-treated rats: detection using polyclonal antibodies raised to histidine-tagged fusion proteins produced and purified from bacteria. Carcinogenesis 19:395-402.
39. Wouters W, Coster RD, Tuman RW, Bowden CR, Bruynseels J, Vanderpas H, Van Rooy P, Amery WK, and Janssen PA (1989) Aromatase inhibition by R 76713: experimental and clinical pharmacology. J Steroid Biochem 34:427-430.
40. Wouters W, Snoeck E, and Coster RD (1994) Vorozole, a specific non-steroidal aromatase inhibitors. Breast Cancer Res Treat 30:89-94.
41. Yang XR, Pfeiffer RM, Garcia-Closas M, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Cartun R, Mandich D, et al. (2007) Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics and risk factor associations in a population-based study. Cancer Res 67:10608-10617.